Anthera Pharmaceuticals Inc  

(Public, NASDAQ:ANTH)   Watch this stock  
Find more results for Debra Adams�
+0.11 (2.53%)
Mar 26 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.05 - 4.58
52 week 1.46 - 6.36
Open 4.19
Vol / Avg. 763,085.00/1.94M
Mkt cap 123.95M
P/E     -
Div/yield     -
EPS -1.37
Shares 28.56M
Beta 1.77
Inst. own 44%
May 11, 2015
Q1 2015 Anthera Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Mar 16, 2015
Q4 2014 Anthera Pharmaceuticals Inc Earnings Release
Mar 4, 2015
Anthera Pharmaceuticals Inc at Cowen Health Care Conference (Breakout Session)
Mar 4, 2015
Anthera Pharmaceuticals Inc at Cowen Health Care Conference
Jan 14, 2015
Anthera Pharmaceuticals Inc at JPMorgan Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -293.28% -144.74%
Return on average equity -2730.85% -473.78%
Employees 20 -
CDP Score - -


25801 Industrial Blvd Ste B
HAYWARD, CA 94545-2223
United States - Map
+1-510-8565600 (Phone)
+1-510-8565597 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases. The Company�s primary Phase 3 product candidate, blisibimod, targets elevated levels of B-cell activating factor (BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus, or lupus, IgA nephropathy, lupus nephritis, multiple myeloma, and others. The Company�s second product candidate, Sollpura (liprotamase), is a Phase III investigational pancreatic enzyme replacement therapy (PERT) intended for the treatment of patients with exocrine pancreatic insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions.

Officers and directors

Christopher S. Henney Ph.D. Independent Chairman of the Board
Age: 74
Bio & Compensation  - Reuters
Paul F. Truex President, Chief Executive Officer, Director
Age: 45
Bio & Compensation  - Reuters
May Liu Senior Vice President - Finance and Administration, Principal Accounting Officer
Age: 38
Bio & Compensation  - Reuters
Debra Odink Ph.D. Senior Vice President, Chief Technology Officer
Age: 50
Bio & Compensation  - Reuters
Paula Adams Ph.D. Senior Vice President - Global Regulatory Affairs and Compliance
Age: 50
Bio & Compensation  - Reuters
Klara A. Dickinson Chief Regulatory Officer, Senior Vice President
Age: 42
Bio & Compensation  - Reuters
Colin Hislop M.D. Senior Vice President, Chief Medical Officer
Age: 56
Bio & Compensation  - Reuters
Brian R. Mueller Director
Age: 40
Bio & Compensation  - Reuters
Philip T. Sager M.D. Director
Bio & Compensation  - Reuters
Steven B. Engle Independent Director
Age: 59
Bio & Compensation  - Reuters